
Sign up to save your podcasts
Or
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
4.3
689689 ratings
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
3,902 Listeners
4,283 Listeners
8,671 Listeners
32,291 Listeners
1,529 Listeners
662 Listeners
111,917 Listeners
2,321 Listeners
6,751 Listeners
2,022 Listeners
5,462 Listeners
15,335 Listeners
4,367 Listeners
8,721 Listeners
10,613 Listeners
1,471 Listeners
459 Listeners